Cyclo Therapeutics Regains Compliance with Nasdaq Standards

Cyclo Therapeutics (CYTH) has released an update.

Cyclo Therapeutics, Inc. has been informed by Nasdaq’s Office of General Counsel that it has rectified its previous deficiency under Listing Rule 5550(b) and is now in compliance with all Nasdaq listing standards. As a result, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and the company’s securities will remain listed and traded on Nasdaq.

For further insights into CYTH stock, check out TipRanks’ Stock Analysis page.